SABS
SAB Biotherapeutics, Inc.
3.98
4 x 2.89
1 x 4.02
bid
ask
+
0.10
2.71%
10:15 AM
timesize
| Ytd | 6.55% | |
| 1y | 127.71% |
3.88
day range
4.04
1.72
52 week range
6.60
| Open | 3.88 | Prev Close | 3.88 | Low | 3.88 | High | 4.04 | Mkt Cap | 308.15M |
| Vol | 26.53K | Avg Vol | 860.41K | EPS | -0.58 | P/E | N/A | Forward P/E | -1.56 |
| Beta | 0.64 | Short Ratio | 1.22 | Inst. Own | 34.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 3.69 | 200-d Avg | 3.58 | 1yr Est | 12.40 |
| Income Statement | |||
| Operating Expenses | 20.00M | ||
| Research and Development Expense | 13.40M | ||
| Selling, General and Administrative Expense | 6.60M | ||
| Operating Income | -20.00M | ||
| Interest Expense | 62.75K | ||
| Net Income | -18.87M | ||
| Net Income Common Stock | -18.87M | ||
| Net Income Common Stock (USD) | -18.87M | ||
| Consolidated Income | -18.87M | ||
| Earnings per Basic Share | -0.35 | ||
| Earnings per Basic Share (USD) | -0.35 | ||
| Earnings per Diluted Share | -0.35 | ||
| Earning Before Interest & Taxes (EBIT) | -18.81M | ||
| Earning Before Interest & Taxes (USD) | -18.81M | ||
| Weighted Average Shares | 53.56M | ||
| Weighted Average Shares Diluted | 53.56M | ||
| Balance Sheet | |||
| Cash and Equivalents | 20.52M | ||
| Cash and Equivalents (USD) | 20.52M | ||
| Investments | 197.11M | ||
| Investments Current | 86.87M | ||
| Investments Non-Current | 110.24M | ||
| Current Assets | 112.78M | ||
| Property, Plant & Equipment Net | 20.17M | ||
| Total Assets | 248.47M | ||
| Debt Current | 920.66K | ||
| Total Debt | 6.17M | ||
| Current Liabilities | 9.85M | ||
| Debt Non-Current | 5.25M | ||
| Total Liabilities | 21.22M | ||
| Accumulated Retained Earnings (Deficit) | -129.76M | ||
| Accumulated Other Comprehensive Income | -222.76K | ||
| Shareholders Equity | 227.25M | ||
| Shareholders Equity (USD) | 227.25M | ||
| Assets Non-Current | 135.69M | ||
| Total Debt (USD) | 6.17M | ||
| Liabilities Non-Current | 11.37M | ||
| Trade and Non-Trade Payables | 3.54M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 752.67K | ||
| Net Cash Flow from Financing | 89.92M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 10.02M | ||
| Capital Expenditure | -981.04K | ||
| Issuance (Purchase) of Equity Shares | 86.99M | ||
| Issuance (Repayment) of Debt Securities | -37.39K | ||
| Net Cash Flow from Investing | -65.65M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -64.67M | ||
| Net Cash Flow from Operations | -14.27M | ||
| Effect of Exchange Rate Changes on Cash | 14.73K | ||
| Share Based Compensation | 5.46M | ||